![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/shutterstock_1997776574.jpg)
AstraZeneca grows oncology portfolio with Pinetree’s EGFR degrader
AstraZeneca has signed a licensing agreement with Pinetree Therapeutics for a preclinical epidermal growth factor receptor (EGFR) degrader candidate, potentially worth more than $545m. AstraZeneca will pay $45m upfront for global developmental and …